Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia

Fig. 3

CAR.CD123-NK cells efficiently recognize and kill primary AML blasts. A Leukaemic cells obtained from BM samples of 3 AML patients (AML#1, AML#3, AML#4) at diagnosis (black bars representing leukaemic cells alone) were cocultured for 6 days with NT-NK (grey bar), or CAR.CD123-NK (line black bar) derived from a single HD. Coculture was performed at an E:T ratio of 1:1. Data of residual CD123+ leukaemic cells is shown as average ± SD. B Granz B, IFN-γ, IL-2 and TNF-α were measured by ELISA assay in 24-h culture supernatant of NT-NK (grey bars) or CAR.CD123-NK cells (line black bars) in response to CD123+ leukaemic cells. C Leukaemic CD123+ cells from BM sample of one single AML patient (AML #2; black bar represent leukaemic cells alone) were cocultured with NT-NK (grey bars) or CAR.CD19-NK (line black bars) derived from 3 independent HDs. Coculture was performed at the E:T ratio of 1:1. Data of residual total CD123+ leukaemic cells is shown as average ± SD. *p < 0.05. D Granz B, IFN-γ, IL-2 and TNF-α were measured by ELISA assay in 24 h culture supernatant of NT-NK (grey bars) or CAR.CD123-NK cells (line black bars) in response to CD123.+ leukaemic cells from AML#2 patient. *p < 0.05

Back to article page